Showing 1371-1380 of 1616 results for "".
- BVI Installs First Beyeonics One Systemhttps://modernod.com/news/bvi-installs-first-beyeonics-one-system/2481035/BVI announced that the first Beyeonics One System has been installed at Holzman Solomon Vision Partners, in McClean, Virginia. On August 17, Jonathon Solomon, MD, was the first US surgeon to offer ophthalmic surgery with the Beyeonics One platform in private practice. Under th
- First SBL-3 ClearView Multifocal Intraocular Lens Implanted in UShttps://modernod.com/news/first-sbl-3-clearview-multifocal-intraocular-lens-implanted-in-us/2481031/Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas. The SBL-3 Clearview Multifocal is a next-generation presbyopia-
- First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/first-patients-treated-with-lensars-ally-adaptive-cataract-treatment-system/2481029/Lensar announced the first commercial cases performed with the ALLY Adaptive Cataract Treatment System by Robert Weinstock, MD, at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent installation of his ALLY Syste
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’